Protein kinase inhibitor-based cancer therapies: considering the potential of nitric oxide (NO) to improve cancer treatment.

Fiche publication

Date publication

février 2020

Journal

Biochemical pharmacology

Auteurs

Membres identifiés du Cancéropôle Est :
Pr BETTAIEB Ali , Pr PAUL Catherine , Dr PLENCHETTE Stéphanie

Tous les auteurs :
Ghione S, Mabrouk N, Paul C, Bettaieb A, Plenchette S

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/32061562

Résumé

The deregulation of a wide variety of protein kinases is associated with cancer cell initiation and tumor progression. Owing to their indispensable function in signaling pathways driving malignant cell features, protein kinases constitute major therapeutic targets in cancer. Over the past two decades, intense efforts in drug development have been dedicated to this field. The development of protein kinase inhibitors (PKIs) have been a real breakthrough in targeted cancer therapy. Despite obvious successes across patients with different types of cancer, the development of PKI resistance still prevails. Combination therapies are part of a comprehensive approach to address the problem of drug resistance. The therapeutic use of nitric oxide (NO) donors to bypass PKI resistance in cancer has never been tested in clinic yet but several arguments suggest that the combination of PKIs and NO donors may exert a potential anticancer effect. The present review summarized the current state of knowledge on common targets to both PKIs and NO. Herein, we attempt to provide the rationale underlying a potential combination of PKIs and NO donors for future directions and design of new combination therapies in cancer.